skip to Main Content

LED Medical Diagnostics Inc. Reports 2018 Second Quarter Results

  • August 29, 2018
  • News Releases

Vancouver, British Columbia – August 29, 2018 – LED Medical Diagnostics Inc. (“LED” or the “Company”), a leading dental imaging technology provider focused on delivering state-of-the-art imaging software and systems, today announced its financial results for the second quarter ended June 30, 2018, reported in United States dollars and in accordance with International Financial Reporting Standards (“IFRS”). The Company’s results are presented in comparison to the first quarter ended March 31, 2018 and second quarter ended June 30, 2017.

Revenue for the three months ended June 30, 2018 was $3,671,432 representing an increase of 10% over the immediately preceding quarter. The Company achieved EBITDA1 of $100,433 during the second quarter of fiscal year 2018 compared to $26,296 in the immediately preceding quarter.

“We  are  experiencing  increasingly  stronger  financial  performance  since  the   Apteryx acquisition in early 2017 and anticipate this trend will continue into the future,” commented LED CEO Dr. David Gane. “Approximately 19% of our total revenues are now recurring or repeatable in nature inclusive of over US$1.5 million in annualized monthly recurring revenue (“MRR”) from our XVWeb® SaaS offering. This number is expected to grow as we execute on our plan”, added Dr. Gane. “XVWeb® is near the leading edge of market  adoption  which  I  expect  will  be  facilitated  by  current  market trends, including the expanding market presence of Dental Support Organizations (“DSOs”), and growth in the number of cloud practice management offerings in the US market with which to partner and gain wider market access.”

Highlights During the Three Months Ended June 30, 2018

  • On April 1, 2018 LED ended its distribution agreement with 3Shape A/S as a reseller of its products and services to focus its resources on its core proprietary imaging devices and software products.
  • On April 24, 2018, the Company entered into an amending agreement which extends the payment terms of the February 10, 2017 Apteryx purchase The deferred cash payment of $350,000 has been extended until November 2019 and will bear interest at 12% per annum.
  • On May 17, 2018, the Company completed a financing of US$200,000 through the issuance of secured debentures maturing after twelve 12 months, bearing an interest rate of 12%.

Financial Highlights for the Three Months Ended June 30, 2018

Revenue for the three months ended June 30, 2018 was $3,671,432 representing an increase of 10% from the three months ended March 31, 2018 and a decrease of 1% from the three months ended June 30, 2017.

The Company’s gross margin2 was 59% for the three months ended June 30, 2018 as compared to 65% for the three months ended March 31 2018 and 57% in the three months ended June 30, 2017.

EBITDA1 for the three months ended June 30, 2018 was $100,433 representing an increase from $26,296 in the prior quarter and ($16,173) from the three months ended June 30, 2017.

Net income was $378,036 for the three months ended June 30, 2018 compared to net income of $905,233 for the three months ended June 30, 2017.

The Company had cash of $1,174,337 as of June 30, 2018. Cash used in operations was

$178,827 during the three months ended June 30, 2018 compared to $1,096,973 during the three months ended June 30, 2017.

Financial Highlights for the Six Months Ended June 30, 2018

Revenue for the six months ended June 30, 2018 was $7,003,298 representing an increase of 21% from the prior year of $5,802,915. The Company’s gross margin2 was 62% for the six months ended June 30, 2018 as compared to 54% in the prior year period. EBITDA1 for the six months ended June 30, 2018 was $126,729 representing an increase from EBITDA1 of ($721,833) in the prior year period. Net income for the six months ended June 30, 2018 was $453,400 representing an increase from net income of ($182,728) in the prior year period.

Financial Statements and Management’s Discussion & Analysis 

Please see the interim consolidated financial statements and related Management’s Discussion & Analysis (“MD&A”) for more details. The interim condensed consolidated financial statements for the three months ended June 30, 2018 and related MD&A have been reviewed and approved by the Company’s Audit Committee and Board of Directors. The Company has prepared this truncated news release to alert investors to its results and that a more detailed explanation and analysis is readily available in the MD&A. These reports have been filed on SEDAR at www.sedar.com and also posted to www.ledmd.com.

About LED Medical Diagnostics Inc.

LED Medical Diagnostics Inc. is a dental imaging technology provider focused on delivering state-of-the-art imaging software and systems. Through its wholly-owned subsidiaries LED Dental Inc., LED Dental Ltd., and Apteryx, Inc., LED Medical has provided dentists and oral health specialists with advanced diagnostic imaging products and software for over 20 years. LED’s proprietary technologies include the VELscope® Vx Enhanced Oral Assessment and TUXEDO Intraoral Sensors, in addition to Apteryx’s XrayVision, XVWeb® and XrayVision DCV imaging software solutions.

Backed by an experienced leadership team and dedicated to a higher level of service and support, LED is committed to providing dental practitioners with the best technology available by identifying and adding leading products to its growing portfolio.

The Company is currently listed on the TSX-V under the symbol LMD, the OTCQB under the symbol LEDIF, as well as the Frankfurt Stock Exchange under the symbol LME.

Media Contact:

LED Dental
Chris Koch
Phone: 678.293.9413
Email: chris.koch@leddental.com

Corporate Contact:

LED Medical
Dr. David Gane, CEO Phone: 604.434.4614 x227
Email: david.gane@leddental.com

 

Forward Looking Statements

This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding, but not limited to the Company’s future growth strategy, its distribution strategy and product offerings, potential expansion of the Company’s technology to other medical applications or markets, or the potential introduction of new technologies by the Company. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation’s actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks, product development risks such as regulatory, design, intellectual property and other factors described in the Corporation’s reports filed on SEDAR including its Annual Information Form and financial report for the year ended March 30, 2018. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

 

1 EBITDA or Earnings before Interest, Taxes, Depreciation and Amortization is a non-IFRS measure that does not have a standardized meaning and may not be comparable to a similar measure disclosed by other issuers. This measure does not have a comparable GAAP measure. EBITDA referenced here relates to net income or loss and comprehensive income or loss less sales and marketing, research and development and administration expenses but excludes interest, income taxes, depreciation, amortization, finder’s warrants issuance costs, stock-based compensation, deferred share unit compensation, mark to market adjustments on Canadian dollar denominated warrants, foreign exchange gain or loss and other income. This measure does not have a comparable IFRS measure and is used by the Company to manage and evaluate the cash operating loss of the business.

 

2 Gross margin is a non-IFRS measure that does not have a standard meaning and may not be comparable to a similar measure disclosed by other issuers. Gross margin referenced here relates to revenues less cost of sales. This measure does not have a comparable IFRS measure and is used by the Company to manage and evaluate the operating performance of the Company.

Back To Top